This company listing is no longer active
DermTech Valuation
Is DMTK * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of DMTK * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate DMTK *'s fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate DMTK *'s fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for DMTK *?
Other financial metrics that can be useful for relative valuation.
What is DMTK *'s n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | US$51.87m |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 1.5x |
Enterprise Value/EBITDA | -0.2x |
PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does DMTK *'s PS Ratio compare to its peers?
Company | Forward PS | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 6.2x | ||
PEB Pacific Edge | 4.8x | n/a | NZ$139.6m |
AADI Aadi Bioscience | 2x | 36.7% | US$47.5m |
HOOK HOOKIPA Pharma | 1.1x | 35.7% | US$57.1m |
A304840 PeopleBio | 17x | n/a | ₩75.8b |
DMTK * DermTech | 3.7x | 29.4% | Mex$51.9m |
Price-To-Sales vs Peers: DMTK * is good value based on its Price-To-Sales Ratio (3.7x) compared to the peer average (18.5x).
Price to Earnings Ratio vs Industry
How does DMTK *'s PE Ratio compare vs other companies in the Global Biotechs Industry?
Price-To-Sales vs Industry: DMTK * is good value based on its Price-To-Sales Ratio (3.7x) compared to the Global Biotechs industry average (9.6x).
Price to Sales Ratio vs Fair Ratio
What is DMTK *'s PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PS Ratio | 3.7x |
Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate DMTK *'s Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.